drugset / Trial / NCT06023758
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter II study to compare KN026 and KN046 versus Oxaliplatin, Capecitabine combined KN026 and KN046 in patients with HER2-positive locally advanced resectable gastric cancer or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2023-09-22
- Primary completion
- 2025-09-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | — |
| Subject | KN026 | Monoclonal antibody | 30 mg/kg | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |